Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited
- P/E ratio
- 139.67
Your view on NEU.AX
Overview
What the company does, where it operates, and who runs it.
About Neuren Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan Charles Pilcher
- Headquarters
- 117 Camberwell Road, Hawthorn East, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan Charles Pilcher
- Headquarters
- 117 Camberwell Road, Hawthorn East, VIC, AU
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome.
The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Neuren Pharmaceuticals Limited from FRC's valuation model, read against the market price. NEU.AX last traded at AUD 22.72, 139.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Neuren Pharmaceuticals Limited. Starting points for Neuren Pharmaceuticals Limited: P/E 139.7, EPS AUD 0.16, beta 1.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Neuren Pharmaceuticals Limited. Trailing twelve-month EPS for Neuren Pharmaceuticals Limited stands at AUD 0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | AUD 0.37 | AUD 0.23 | AUD 0.41 | AUD 0.58 |
| Lowest estimate | AUD 0.37 | AUD 0.23 | AUD 0.37 | AUD 0.53 |
| Highest estimate | AUD 0.37 | AUD 0.23 | AUD 0.45 | AUD 0.71 |
| Number of analysts | 1 | 1 | 4 | 4 |
| A year ago | AUD 1.03 | AUD 0.12 | AUD 0.231 | — |
| Growth vs a year ago | −63.9% | +96.8% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | AUD 94.17M | AUD 45.40M | AUD 132.23M | AUD 178.57M |
| Lowest estimate | AUD 94.17M | AUD 45.40M | AUD 129.13M | AUD 172.17M |
| Highest estimate | AUD 94.17M | AUD 45.40M | AUD 138.82M | AUD 186.01M |
| Number of analysts | 1 | 1 | 4 | 4 |
| A year ago | AUD 192.50M | AUD 28.28M | AUD 64.63M | — |
| Growth vs a year ago | −51.1% | +60.6% | +104.6% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ENP.AXEntropy Neurodynamics Limited | Healthcare | Biotechnology | — | ||
| IXC.AXInvex Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | Biotechnology | — | ||
| NYR.AXNyrada Inc. | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ORMPOramed Pharmaceuticals Inc. | Healthcare | NASDAQ | $169.2M | ||
| ORPOFOSE Immunotherapeutics S.A. | Healthcare | OTC | $260.3M | ||
| ORYZFOryzon Genomics S.A. | Healthcare | OTC | $283.9M | ||
| OSRHWOSR Holdings, Inc. | Healthcare | NASDAQ | $7.8M | ||
| OSTXOS Therapies Incorporated | Healthcare | AMEX | $48.1M | ||
| OTLCOncotelic Therapeutics, Inc. | Healthcare | OTC | $21.2M | ||
| OTLKOutlook Therapeutics, Inc. | Healthcare | NASDAQ | $99.3M | ||
| OVIDOvid Therapeutics Inc. | Healthcare | NASDAQ | $426.5M | ||
| OXBOFOxford BioDynamics Plc | Healthcare | OTC | $4.3M | ||
| OZYMFStrategic Partners A/S | Healthcare | OTC | $3.7M | ||
| PAB.AXPatrys Limited | Healthcare | ASX | — | ||
| PALIPalisade Bio, Inc. | Healthcare | NASDAQ | $168.9M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| IEFAiShares Core MSCI EAFE ETF | $188.8B in assets | 0.01% | |
| AVDVAvantis International Small Cap Value ETF | $19.2B in assets | 0.05% | |
| ISCFiShares International Small-Cap Equity Factor ETF | $717M in assets | 0.12% | |
| AVDSAvantis International Small Cap Equity ETF | $379M in assets | 0.07% | |
| DFISDimensional - International Small Cap ETF | $5.8B in assets | 0.04% | |
| DLSWisdomTree International SmallCap Dividend Fund | $1.0B in assets | 0.04% | |
Largest holders first, then the funds most concentrated in NEU.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Neuren Pharmaceuticals Limited. Coverage tracks Neuren Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Neuren Pharmaceuticals Limited.